Celularity Inc

GX Acquisition Corp. II (Nasdaq: GXGX), sponsored by GX Sponsor II LLC, was a blank-check company that completed its initial public offering in 2020 targeting the life sciences and biotechnology sector. An 8-K filed July 22, 2021 reported the closing of the company's business combination with Celularity Inc., a clinical-stage biotechnology company founded by Dr. Robert Hariri that develops placenta-derived allogeneic cell therapies across oncology and degenerative disease indications. Following the transaction close, the combined company began trading on Nasdaq under the ticker CELU, with Celularity operating as a public entity. For comprehensive data on GXGX and thousands of other SPAC transactions, create a free account at SpacDesk.